Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Pediatric Oncology

What Are MAP Chemotherapy Side Effects in Osteosarcoma?

At a Glance

MAP chemotherapy for osteosarcoma commonly causes nausea, vomiting, mouth sores, hair loss, and low infection-fighting white blood cells. Fever when these cells are low is an emergency, while kidney, heart, and hearing checks help detect serious treatment effects early.

Children and teens receiving the MAP chemotherapy regimen—which stands for Methotrexate, Adriamycin (doxorubicin), and Platinol (cisplatin)—for osteosarcoma are likely to experience several common side effects during their treatment [1]. While treatment often spans an estimated 8 to 10 months, the exact timeline depends on your child’s specific protocol, surgery timing, and any treatment delays [2]. Because Adriamycin directly affects rapidly dividing cells, hair loss is a very common and visible change [3]. However, the medical team will be equally focused on managing severe nausea, painful mouth sores, and a weakened immune system that puts your child at risk for dangerous infections [4][5][6]. Because MAP uses intensive doses of powerful medications, the care team will also actively monitor and protect the heart, hearing, and kidneys [7][8][9]. Your child’s individualized care plan takes precedence, but knowing what to expect can help you prepare for the day-to-day realities of treatment.

The Emergency of Fever and Immune Suppression

MAP significantly suppresses the bone marrow, leading to a drop in the Absolute Neutrophil Count (ANC), a condition called neutropenia [10]. Neutrophils are the specific white blood cells that fight off bacterial infections. Your child’s risk of infection depends on how low the ANC drops and how long it stays low.

  • When to Call Immediately: A fever while neutropenic (febrile neutropenia) is a medical emergency [4]. Without neutrophils, an infection can rapidly become life-threatening and may require prompt intravenous (IV) antibiotics [11].
  • Your Action Plan: Your oncology team will provide an exact temperature threshold—often a single reading of 101°F (38.3°C) or 100.4°F (38.0°C) sustained for an hour [4]. If your child reaches this, call the 24-hour oncology line immediately and follow their instructions on where to go. Do not simply go to any emergency room unless instructed, do not wait to see if the fever breaks, and never give acetaminophen (Tylenol) or ibuprofen (Advil/Motrin) to bring the fever down without explicit permission, as this masks the infection. Never take a rectal temperature when your child’s blood counts are low, as it can tear the tissue and introduce bacteria.
  • Growth Factors: To help reduce the duration of neutropenia, doctors may prescribe G-CSF (growth factor injections) for selected cycles to stimulate the bone marrow [10].

Nausea, Vomiting, and Hydration

Both cisplatin and doxorubicin are highly likely to cause severe nausea and vomiting [5].

  • Management Plan: The care team will prescribe a scheduled regimen of preventive anti-nausea medications (antiemetics). This often includes a combination of drugs like 5-HT3 antagonists (e.g., palonosetron) and steroids (e.g., dexamethasone), plus “rescue” medications for breakthrough nausea [5].
  • What You Can Do: Give scheduled medications exactly as prescribed, even if your child feels fine. If your child vomits a dose, do not double up or repeat it—call the oncology team for advice. Also, be aware that doxorubicin (Adriamycin) is red and can turn your child’s urine pink or red for a day or two after infusion; this is normal and not blood.
  • When to Call: Call your team promptly if your child experiences repeated vomiting, cannot keep fluids or medications down, or shows signs of dehydration (such as significantly reduced urination).

Hair Loss (Alopecia)

Chemotherapy targets rapidly dividing cells, including hair follicles [3].

  • What to Expect: Hair loss usually begins within a few weeks of treatment. Your child may lose head hair, eyelashes, eyebrows, and body hair.
  • Management: Ask your team if scalp cooling (a method to reduce hair loss) is appropriate and available for your child’s specific regimen, though it is not always recommended or successful. Hair will usually grow back over the weeks and months after treatment ends, though it can sometimes temporarily change in texture or color.

Mouth Sores (Mucositis)

Methotrexate and doxorubicin can cause mucositis—inflammation and painful sores in the mouth and throat [6].

  • What to Expect: These sores can make chewing and swallowing very painful.
  • Management: Gentle oral hygiene is essential. Use soft-bristled toothbrushes and only the specific, non-irritating (alcohol-free, peroxide-free) mouth rinses your team prescribes [6]. Sucking on ice chips (oral cryotherapy) during certain chemotherapy infusions can reduce mouth sores, but only use this if the oncology team specifically approves it for that drug [12].
  • When to Call: Contact the team early if pain prevents your child from drinking, swallowing pills, or urinating, or if you suspect an infection [13]. Severe cases may require strong pain medications or temporary IV nutrition [14][15].

Protecting the Kidneys, Heart, and Hearing

MAP requires active monitoring to protect long-term organ function.

  • Kidneys and Methotrexate: High-dose methotrexate can cause kidney damage and must be cleared from the body safely [1][9]. To ensure this, your child will receive large amounts of IV fluids containing sodium bicarbonate to alkalinize (reduce the acidity of) their urine. They will also receive a rescue drug called leucovorin and have their blood drawn repeatedly to check methotrexate levels until the drug is safely cleared [1]. Always ask the oncology team before giving any new medication, over-the-counter drug, or supplement (especially NSAIDs like ibuprofen), as they can dangerously interact with methotrexate clearance [1].
  • Heart: Doxorubicin can affect the heart muscle [7]. The team will perform regular echocardiograms (ultrasounds of the heart) to monitor heart function during and long after treatment [7]. Report shortness of breath, swelling, fainting, chest pain, or palpitations promptly.
  • Hearing: Cisplatin can cause hearing loss or ringing in the ears (ototoxicity) [8]. Regular hearing tests (audiograms) will monitor for changes [8]. Hearing damage can be permanent, so report any ringing (tinnitus) or difficulty hearing high-pitched sounds immediately.

Common questions in this guide

What side effects are common with MAP chemotherapy for osteosarcoma?
Common effects include nausea and vomiting, hair loss, painful mouth sores, and low infection-fighting white blood cell counts. The care team also watches kidney function, heart function, and hearing because methotrexate, doxorubicin, and cisplatin can affect these organs.
What should I do if my child develops a fever during MAP treatment?
Use the temperature threshold given by your child's oncology team; common instructions include one reading of 101°F (38.3°C) or a temperature of 100.4°F (38.0°C) sustained for an hour. Call the 24-hour oncology line immediately and follow instructions about where to go. Do not wait for the fever to break, give acetaminophen or ibuprofen without permission, or take a rectal temperature.
How can nausea and vomiting from MAP chemotherapy be managed?
Give preventive anti-nausea medicines on schedule, even when your child feels well, and use prescribed rescue medicine for breakthrough symptoms. If your child vomits a dose, do not repeat or double it without advice; call the oncology team if vomiting continues or your child cannot keep fluids or medicines down or is urinating much less.
How should we care for mouth sores during MAP treatment?
Use a soft toothbrush and only mouth rinses specifically recommended by the oncology team, such as alcohol-free and peroxide-free products. Ask before using ice chips during an infusion, and call promptly if pain prevents drinking, swallowing pills, or urinating.
Why does high-dose methotrexate require extra fluids and leucovorin?
High-dose methotrexate needs to be cleared safely through the kidneys. IV fluids with sodium bicarbonate, leucovorin, and repeated blood tests for methotrexate levels help the team support safe clearance. Ask the oncology team before giving any new medicine, over-the-counter drug, or supplement, especially ibuprofen.
How are heart and hearing problems monitored during MAP chemotherapy?
Doxorubicin can affect the heart muscle, so the team uses echocardiograms during and after treatment. Cisplatin can cause permanent hearing changes, so audiograms check hearing; report ringing in the ears or trouble hearing high-pitched sounds promptly.
How long does MAP chemotherapy for osteosarcoma usually last?
Treatment often spans about 8 to 10 months, but the timeline varies with the child's protocol, surgery timing, and any treatment delays. The oncology team can provide the schedule that applies to your child's care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What exact temperature threshold do you use to define a fever, which thermometer should we use, and where exactly should we go if a fever happens after hours?
  2. 2.Can you provide a written, daily anti-nausea medication schedule detailing which drugs are given preventively and which are for 'rescue'?
  3. 3.What is the plan for high-dose methotrexate admissions (e.g., fluid requirements, leucovorin rescue), and how long do these hospital stays typically last?
  4. 4.What specific oral care products (like mouthwashes or soft brushes) do you recommend, and what should we do if my child is in too much pain to drink?
  5. 5.How often will my child have echocardiograms (heart ultrasounds) and audiograms (hearing tests) during the treatment months?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.

    Wippel B, Gundle KR, Dang T, et al.

    Cancer medicine 2019; (8(1)):111-116 doi:10.1002/cam4.1898.

    PMID: 30580500
  2. 2

    Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients.

    Kasi PM, Grothey A

    Drugs 2018; (78(7)):737-745 doi:10.1007/s40265-018-0909-3.

    PMID: 29754293
  3. 3

    Hair-Shaft Growth in Gelfoam® Histoculture of Skin and Isolated Hair Follicles.

    Hoffman RM, Li L, Cao W

    Methods in molecular biology (Clifton, N.J.) 2018; (1760()):133-144 doi:10.1007/978-1-4939-7745-1_14.

    PMID: 29572801
  4. 4

    Neutropenia: Evaluation and Management in the Primary Care Setting.

    Kim MJ, Forlini C, Kremsreiter K

    American family physician 2025; (112(6)):618-628.

    PMID: 41533406
  5. 5

    Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial.

    Li Z, Li C, Li P, et al.

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2022; (31(3)):223-230 doi:10.17219/acem/142332.

    PMID: 35302300
  6. 6

    Mouth-rinses for the prevention of chemotherapy induced oral mucositis in children: a systematic review.

    Hashemi A, Bahrololoumi Z, Khaksar Y, et al.

    Iranian journal of pediatric hematology and oncology 2015; (5(2)):106-12.

    PMID: 26131350
  7. 7

    Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group.

    Kopp LM, Womer RB, Schwartz CL, et al.

    Cardio-oncology (London, England) 2019; (5()):15 doi:10.1186/s40959-019-0050-9.

    PMID: 32154021
  8. 8

    Long-term renal outcomes of children with cancers treated with platinum-based chemotherapy: A retrospective chart analysis.

    Kan A, Marokakis S, Ward JH, et al.

    Pediatric blood & cancer 2025; (72(1)):e31404 doi:10.1002/pbc.31404.

    PMID: 39503057
  9. 9

    Chronic kidney disease consecutive to chemotherapy for chondroblastic osteosarcoma: A report on 6 pediatric cases.

    Paul A, Duncan A, Bacchetta J, et al.

    Nephrologie & therapeutique 2021; (17(7)):543-546 doi:10.1016/j.nephro.2021.05.004.

    PMID: 34229968
  10. 10

    Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences.

    Badr M, Hassan T, Sakr H, et al.

    Molecular and clinical oncology 2016; (5(3)):300-306 doi:10.3892/mco.2016.957.

    PMID: 27588196
  11. 11

    Consensus document on the management of febrile neutropenia in paediatric haematology and oncology patients of the Spanish Society of Pediatric Infectious Diseases (SEIP) and the Spanish Society of Pediatric Hematology and Oncology (SEHOP).

    Martínez Campos L, Pérez-Albert P, Ferres Ramis L, et al.

    Anales de pediatria 2023; (98(6)):446-459 doi:10.1016/j.anpede.2023.03.010.

    PMID: 37268527
  12. 12

    Photobiomodulation as a preventive strategy for oral mucositis in pediatric oncology: a systematic review and meta-analysis.

    Marques MT, Arêde LT, Rodrigues JVS, et al.

    Journal of dentistry 2025; (162()):106074 doi:10.1016/j.jdent.2025.106074.

    PMID: 40889543
  13. 13

    A new emerging oral infection: Raoultella planticola in a boy with haematological malignancy.

    Bardellini E, Amadori F, Schumacher RF, et al.

    European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry 2017; (18(3)):215-218 doi:10.1007/s40368-017-0279-7.

    PMID: 28349509
  14. 14

    Methylene Blue for the Treatment of Intractable Pain Associated with Oral Mucositis.

    Roldan CJ, Nouri K, Chai T, Huh B

    Pain practice : the official journal of World Institute of Pain 2017; (17(8)):1115-1121 doi:10.1111/papr.12566.

    PMID: 28226414
  15. 15

    Clinical Outcome in Children with Chemotherapy-Induced Mucositis.

    Otmani N, Hattad S

    Seminars in oncology nursing 2021; (37(3)):151160 doi:10.1016/j.soncn.2021.151160.

    PMID: 34088558

This page is for informational purposes only and does not constitute medical advice. Your child's oncology team should provide individualized instructions for fever, medications, and side-effect care.

Get notified when new evidence is published on Osteosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.